Carfilzomib experience in relapsed/refractory multiple myeloma: a single-center experience

Basit Öğe Kaydı
dc.authoridUYSAL, AYŞE/0000-0002-5581-8104
dc.authoridComert, Melda/0000-0002-7798-4349
dc.authoridSahin, Fahri/0000-0001-9315-8891
dc.authorwosidSaydam, Guray/W-3827-2017
dc.authorwosidUYSAL, AYŞE/HJB-3073-2022
dc.authorwosidComert, Melda/ABH-5764-2020
dc.authorwosidSahin, Fahri/AAA-2768-2020
dc.contributor.authorUysal, Ayse
dc.contributor.authorAkad Soyer, Nur
dc.contributor.authorOzkan, Melda
dc.contributor.authorSahin, Fahri
dc.contributor.authorVural, Filiz
dc.contributor.authorTobu, Mahmut
dc.contributor.authorTombuloglu, Murat
dc.date.accessioned2024-08-04T20:09:53Z
dc.date.available2024-08-04T20:09:53Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground/aim: Carfilzomib (CFZ) is a new-generation proteasome inhibitor with significant activity in relapsed or refractory multiple myeloma (R/R-MM). We have retrospectively evaluated R/R-MM patients who were treated with CFZ plus dexamethasone. Materials and methods: Twenty-one R/R-MM patients who were treated with CFZ plus dexamethasone between October 2013 and January 2016 were screened. The patients were followed until March 2016 after CFZ treatment. Results: Ten (47.6%) of the patients were female and 11 (52.4%) of them were male. The median age was 62 (47-76) years. The median number of prior treatment lines was 3 (2-7). The median number of administered cycles of treatment for CFZ was 4 (1-10). The median overall response rate was 26.3%. The most common hematological adverse events were anemia and thrombocytopenia (38%). The most common nonhematological adverse event was fatigue (71.4%). One patient died because of a cerebrovascular event and 1 patient died because of pneumonia during the treatment period. The median duration of response rate and time to next therapy were 8 (7-9) and 3 (2-16) months, respectively. The median overall survival was 8 (0.5-33) months. Conclusion: Despite the small number of patients, our results suggest that CFZ provides acceptable responses in heavily pretreated R/R-MM patients.en_US
dc.identifier.doi10.3906/sag-1611-97
dc.identifier.endpage83en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue1en_US
dc.identifier.pmid29479960en_US
dc.identifier.scopus2-s2.0-85042471870en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage80en_US
dc.identifier.trdizinid299121en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1611-97
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/299121
dc.identifier.urihttps://hdl.handle.net/11616/92490
dc.identifier.volume48en_US
dc.identifier.wosWOS:000425902900014en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technological Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultiple myelomaen_US
dc.subjectcarfilzomiben_US
dc.subjectproteasome inhibitorsen_US
dc.subjectnovel therapiesen_US
dc.titleCarfilzomib experience in relapsed/refractory multiple myeloma: a single-center experienceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu